Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021

SELL
$46.83 - $73.5 $633,282 - $993,940
-13,523 Closed
0 $0
Q2 2021

Aug 13, 2021

BUY
$37.41 - $62.25 $505,895 - $841,806
13,523 New
13,523 $719 Million

Others Institutions Holding ZNTL

About Zentalis Pharmaceuticals, Inc.


  • Ticker ZNTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,983,600
  • Market Cap $171M
  • Description
  • Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...
More about ZNTL
Track This Portfolio

Track Alpha Paradigm Partners, LLC Portfolio

Follow Alpha Paradigm Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alpha Paradigm Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alpha Paradigm Partners, LLC with notifications on news.